Global Expansion Santen Pharmaceutical has a strong international presence, reaching patients in over 60 countries and regions, which indicates significant opportunities to develop and customize sales strategies for diverse markets, especially in regions where ophthalmology treatments are growing.

Strategic Partnerships Recent collaborations with Novartis Korea and licensing agreements with RemeGen suggest a focus on expanding product offerings and entering new markets through partnerships, providing avenues for sales teams to leverage co-marketing and distribution channels.

Innovative Product Launches Santen's launch of new ophthalmic products like low-dose atropine and TAPCOM in key markets such as Germany and China shows ongoing product innovation, creating potential sales opportunities for advanced ophthalmic solutions.

Research & Development Focus With a history rooted in scientific research and recent investments in new eye disease treatments, Santen remains at the forefront of ophthalmology innovation, offering opportunities for selling cutting-edge pharmaceuticals and medical devices.

Market Leadership & Growth As a market leader in prescription ophthalmic pharmaceuticals in Japan with consistent expansions and new product launches, Santen’s growth trajectory indicates strong future sales potential across existing and emerging markets.